VEGFA and renal cell adenocarcinoma: It is currently unclear if RCC patients who respond to the combination of erlotinib and bevacizumab similarly have a gain-of-function mutation within the tyrosine kinase active site and/or if they simply overexpress EGFR/ligand or VEGF/receptor.